Raymond James Financial Inc. Invests $6.85 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 189,364 shares of the specialty pharmaceutical company's stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned about 0.34% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock worth $27,242,000 after purchasing an additional 40,968 shares during the period. Bank of New York Mellon Corp lifted its position in Supernus Pharmaceuticals by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock valued at $14,449,000 after purchasing an additional 27,134 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Supernus Pharmaceuticals by 4.0% during the fourth quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company's stock valued at $10,730,000 after purchasing an additional 11,321 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Supernus Pharmaceuticals by 40.6% in the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock worth $7,901,000 after purchasing an additional 73,118 shares during the last quarter.

Remove Ads

Supernus Pharmaceuticals Trading Up 0.3 %

NASDAQ:SUPN traded up $0.09 during mid-day trading on Thursday, reaching $32.42. The company's stock had a trading volume of 402,694 shares, compared to its average volume of 466,242. The stock has a market cap of $1.81 billion, a P/E ratio of 30.30 and a beta of 0.83. The firm's fifty day moving average price is $35.37 and its two-hundred day moving average price is $35.03. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SUPN. StockNews.com lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Activity

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 over the last three months. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.